`
`UNITED STA TES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`111651,212
`
`0110912007
`
`Irit Pinchasi
`
`75667/JPW/GJG/ALW
`
`1141
`
`03/09/2010
`
`23432
`7590
`COOPER & DUNHAM, LLP
`30 Rockefeller Plaza
`20th Floor
`NEW YORK, NY 10112
`
`EXAMINER
`
`RUSSEL, JEFFREY E
`
`ART UNIT
`
`PAPER NUMBER
`
`1654
`
`MAILDATE
`
`DELIVERY MODE
`
`03/09/2010
`
`PAPER
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`PTOL-90A (Rev. 04/07)
`
`Page 1 of 2
`
`YEDA EXHIBIT NO. 2037
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`
`
`Application No.
`
`Applicant(s)
`
`Notice of Abandonment
`
`11/651,212
`Examiner
`
`PINCHAS!, IRIT
`Art Unit
`
`Jeffrey E. Russel
`1654
`-- The MAILING DA TE of this communication appears on the cover sheet with the correspondence address--
`
`This application is abandoned in view of:
`
`1. ~ Applicant's failure to timely file a proper reply to the Office letter mailed on 20 Julv 2009.
`(a) DA reply was received on __ (with a Certificate of Mailing or Transmission dated __ ), which is after the expiration of the
`period for reply (including a total extension of time of __ month(s)) which expired on __ .
`(b) DA proposed reply was received on __ , but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection.
`
`(A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the
`application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for
`Continued Examination (RCE) in compliance with 37 CFR 1.114).
`(c) DA reply was received on __ but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non(cid:173)
`final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
`
`(d) ~ No reply has been received.
`
`2. D Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months
`from the mailing date of the Notice of Allowance (PTOL-85).
`(a) D The issue fee and publication fee, if applicable, was received on __ (with a Certificate of Mailing or Transmission dated
`__ ),which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of
`Allowance (PTOL-85).
`(b) D The submitted fee of$ __ is insufficient. A balance of$ __ is due.
`The issue fee required by 37 CFR 1.18 is$ __ . The publication fee, if required by 37 CFR 1.18(d), is$ __ .
`
`(c) D The issue fee and publication fee, if applicable, has not been received.
`
`3.0 Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of
`Allowability (PT0-37).
`(a) D Proposed corrected drawings were received on __ (with a Certificate of Mailing or Transmission dated __ ), which is
`after the expiration of the period for reply.
`
`(b) D No corrected drawings have been received.
`
`4. D The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of
`the applicants.
`
`5. D The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR
`1.34(a)) upon the filing of a continuing application.
`
`6. D The decision by the Board of Patent Appeals and Interference rendered on __ and because the period for seeking court review
`of the decision has expired and there are no allowed claims.
`
`7. D The reason(s) below:
`
`/Jeffrey E. Russel/
`Primary Examiner, Art Unit 1654
`
`Petitions to revive under 37 CFR 1.137(a) or (b ), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to
`minimize any ne!=)ative effects on patent term.
`U.S. Patent and Trademark Office
`PTOL-1432 (Rev. 04-01)
`
`Notice of Abandonment
`
`Part of Paper No. 20100302
`
`Page 2 of 2
`
`YEDA EXHIBIT NO. 2037
`MYLAN PHARM. v YEDA
`IPR2015-00644